Pharmaceutical Companies Look Beyond Capacity When Choosing European CDMO Partners
A manufacturing delay can create setbacks that extend beyond the production timeline. For companies developing biologic medicines, problems during technology transfer or unexpected process issues can affect clinical supply schedules and add pressure to development budgets. These concerns are changing how pharmaceutical companies evaluate external manufacturing partners.
European CDMOs are increasingly being judged on more than their ability to produce drug material. Pharmaceutical companies are looking closely at how these manufacturers support development activities, communicate technical information and handle the complexity of biologics production.
Capacity and production cost have traditionally been major factors in outsourcing decisions. They remain important, but they do not provide the full picture. A CDMO may have available manufacturing space, yet still struggle if its teams do not have the experience needed to manage a specific process or product requirement.
Technology transfer has become one of the most closely examined stages of a CDMO relationship. Moving a manufacturing process from a pharmaceutical company’s laboratory or another production site requires detailed coordination around methods, equipment requirements and quality documentation.
This is where many European CDMOs are being asked to play a larger role. Their involvement often starts before commercial production begins, requiring collaboration between scientists, engineers and manufacturing teams to ensure the process can move into a regulated production environment.
The shift is also changing how pharmaceutical companies compare potential partners. Instead of looking at CDMOs simply as outsourced manufacturing sites, buyers are assessing the level of technical support available during development and production activities.
This is really important for biotechnology companies. A lot of drug developers have good research programs, but they do not have the ability to make their own products.
They can work with a CDMO to go from making something in a laboratory to making it for people to use without having to do everything by themselves. This way, biotechnology companies can make progress without having to build everything they need from the start.
Larger pharmaceutical companies are also reviewing their outsourcing models. Even those with internal manufacturing resources may turn to CDMOs when they need additional production capacity, access to specialized processes or expertise in a particular technology area.
The European CDMO market includes manufacturers with different areas of focus. Some have deeper experience in specific biological systems, while others support a broader range of production requirements. This gives pharmaceutical companies more choice, but it also makes partner selection more detailed.
When it comes to making decisions, quality systems are really important. Pharmaceutical companies have to make sure that the people they work with to make their products are doing everything correctly and following all the rules. This means that these companies, known as pharmaceutical companies, need to keep good records of everything that happens during production. The relationship between a company and a company that makes their products for them, which is called a CDMO, depends on being able to keep up these good standards for a long time.
The increasing complexity of biologic medicines is likely to keep changing how pharmaceutical companies approach outsourcing. Production output alone does not define a CDMO’s role. Technical knowledge, collaboration during development and the ability to address process issues are becoming important factors in partner evaluations.
When you are buying something, you need to pick a company that makes things for other people. This company should be able to do what you need them to do, depending on what you're making and how far along you are. You have to think about what this European company can do. If it is a good match for your product and where you are, in the process. This is what buyers do when they are choosing a European CDMO. Capacity may begin the conversation, but technical compatibility often determines whether the partnership can support the product over the longer term.
